Jeffrey Bornstein

Jeffrey Bornstein

Company: Eledon Pharmaceuticals Inc.

Job title: Chief Medical Officer

Seminars:

– Evaluating a Next Generation Anti-CD40L Antibody as a Therapy for Patients with ALS 11:30 am

The rationale for targeting CD40L in patients with ALS Results of a pilot study targeting CD40L in patients with ALS Looking to the future with targeting CD40L in patients with ALSRead more

day: Day Two AM

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.